Friday, July 31, 2026

Is the Bond Market Making a Comeback? Discover Why Investors Are Turning to U.S. Treasuries in 2026

U.S. Treasury bonds face losses post-war, yet Wall Street shows renewed interest amid economic concerns and high yields.

Psychiatrists See Promise in Generative AI for Mental Health Care, but Not as a Replacement for Clinicians

South Korean psychiatrists see generative AI as a supportive tool for mental health but caution against replacing human clinicians.

How Huawei’s 5G Advanced Will Transform AI Connectivity Before 6G Arrives

Huawei urges early adoption of 5G Advanced to meet AI demands, predicting explosive growth in AI and emphasizing network upgrades.

Tag: Alzheimer's

Neurophet AQUA AD Plus: The Innovative AI Tool Designated for Public Health in 2026

Neurophet's Alzheimer's treatment solution, Neurophet AQUA AD Plus, gains innovative product status, enhancing public procurement access.

Neurophet to showcase Alzheimer’s imaging platform at AAIC 2026

Neurophet will showcase its AI-driven brain imaging solutions at AAIC 2026, aiming to partner with global pharmaceutical firms for Alzheimer's treatment.

China’s Fosun Pharma invests $27.5 million in AriBio, boosting optimism for Korean Alzheimer’s drug

Fosun Pharma invests $27.5 million in South Korea's AriBio, boosting its Alzheimer’s drug development and global commercialization efforts.

New Study Suggests Ginkgo Biloba Extract May Slow Beta-Amyloid Aggregation in Mild Cognitive Impairment

Ginkgo biloba extract shows promise in inhibiting beta-amyloid aggregation, potentially preventing Alzheimer's in MCI patients.

AriBio Advances Global Alzheimer’s Strategy With Multibillion-Dollar AR1001 Licensing Deal

AriBio secures a $4.67 billion licensing deal for Alzheimer's drug AR1001 with Puxing Pharmaceutical, aiming for global commercialization.

MSD Korea Announced at Bio Korea 2026 that Korea is a Crucial Hub for Global Innovation

Korea is now a key innovation hub for MSD, focusing on neuroscience and clinical research collaborations, with significant R&D investments.

Significant Weight Loss Substantially Increases Mortality Risk in Dementia Patients

A study finds dementia patients with significant weight loss face higher mortality risks, while stable weight or moderate gain lowers risks.

Unlocking Alzheimer’s: The Surprising Role of Tau Protein in Cell Division Revealed

POSTECH researchers reveal tau protein's new role in DNA interaction, impacting Alzheimer's, infertility, and congenital disorders.

Neurophet AQUA AD Plus: Revolutionizing Alzheimer’s Diagnosis with AI at AD/PD 2026

Neurophet showcased its AI solutions for Alzheimer's at AD/PD 2026, aiming to foster collaborations in treatment development.

Korean Medical AI Lands at the University of Washington: Neurofit Signs U.S. Deal for Brain MRI + PET Analysis Tools

Neurofit signs a contract to supply AI medical solutions to the University of Washington, marking its U.S. market entry and expansion.

How Neurophet AQUA is Transforming Dementia Diagnosis in South Korea: Key MOU Insights

Neurophet partners with Eisai Korea to enhance dementia screening and diagnostics using AI-based software, Neurophet AQUA.

Early-Onset Dementia: The Growing Need for Early Detection and Prevention

Early-onset dementia affects those under 65, with symptoms requiring early recognition and treatment for better outcomes.

Study Reveals: Taking Statins for 3 Years Can Slash Dementia Risk by 63%!

A study reveals statins can reduce dementia risk by 63%, especially in diabetic patients, highlighting their protective benefits.

Top News

- Our Sponsors Ad -

Follow us